PD-(L)1×VEGF bispecific antibodies in solid tumors: clinical trial updates from ASCO 2026
A new antibody combining two mechanisms—immune checkpoint activation and anti-angiogenesis—extends survival in advanced lung cancer better than standard immunotherapy alone.
This review reports phase 3 HARMONi-6 trial results from ASCO 2026, demonstrating OS benefit for ivonescimab—a PD-(L)1×VEGF bispecific antibody—plus chemotherapy over standard immunotherapy in advanced NSCLC. The finding validates a novel class of bispecific antibodies that combine immune checkpoint blockade and VEGF inhibition in a single molecule to overcome angiogenesis-mediated immune resistance.
What the study was
- Study design
- Clinical review summarizing phase 3 randomized trial data
- Population
- Previously untreated advanced/metastatic NSCLC patients
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Journal of hematology & oncology
Why it surfaced
Phase 3 OS benefit for novel PD-L1×VEGF bispecific antibody in NSCLC at ASCO 2026; advances the bispecific antibody class in one of the highest-incidence cancers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.